East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Trazodone Hydrochloride Tablets, 50 mg, 100 mg, 150 mg, and 300 mg. Aurobindo’s Trazodone Hydrochloride Tablets, 50 mg, 100 mg, 150 mg, and 300 mg are an AB-rated generic equivalent to the reference listed drug, Desyrel Tablets, 50 mg, 100 mg, 150 mg, and 300 mg, of Pragma Pharmaceuticals, LLC (Pragma).

Trazodone Hydrochloride Tablets are a selective serotonin reuptake inhibitor indicated for the treatment of major depressive disorder (MDD).

Trazodone Hydrochloride Tablets has an estimated market size of US $123 Million for the twelve months ending December 2019 as per IQVIA.